IL-17 in obesity and adipogenesis

Cytokine Growth Factor Rev. 2010 Dec;21(6):449-53. doi: 10.1016/j.cytogfr.2010.10.005. Epub 2010 Nov 16.

Abstract

The pro-inflammatory cytokine interleukin (IL)-17 (also known as IL-17) has been associated with induction of tissue inflammation. Obese individuals exhibit many symptoms of chronic low-grade inflammation, suggesting that IL-17 may impact adipose tissue. However, the role of IL-17 in obesity is largely unexplored. Emerging studies indicate that obesity selectively promotes expansion of the Th17 T-cell lineage, exacerbating disease in murine models of autoimmunity such as EAE and colitis. Human studies support this concept, as new clinical studies suggest that IL-17 is expressed at elevated levels in obese individuals. Conversely, however, an anti-adipogenic role for IL-17 is becoming evident, and therefore the interconnections between IL-17 and fat metabolism may be quite complex. Here, we consolidate the potential implications of IL-17 in relation to obesity and describe the emerging data regarding the role of IL-17 in adipose tissue.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adipogenesis / physiology*
  • Animals
  • CCAAT-Enhancer-Binding Protein-beta / physiology
  • Cell Differentiation
  • Cyclooxygenase 2 / physiology
  • Humans
  • Inflammation / physiopathology
  • Interleukin-17 / biosynthesis
  • Interleukin-17 / immunology*
  • Interleukin-6 / biosynthesis
  • Mice
  • Obesity / immunology*
  • Obesity / physiopathology
  • Th17 Cells / physiology

Substances

  • CCAAT-Enhancer-Binding Protein-beta
  • Interleukin-17
  • Interleukin-6
  • Cyclooxygenase 2